相关实验视频
Updated: Jun 1, 2025

07:51
Video Movement Analysis Using Smartphones ViMAS: A Pilot Study
Published on: March 14, 2017
16.7K
沃伊塔疗法对唐氏综合征患者的步行能力的直接影响:试点研究
Guoping Qian1, Ewelina Perzanowska1, Mirela Kozakiewicz1
1Department of Physical Culture, Gdansk University of Physical Education and Sport, Gdansk, Poland.
Frontiers in neurology
|January 21, 2025
概括
沃伊塔疗法 (VT) 对唐氏综合征 (DS) 患者显示出立即的好处,在单次治疗后显著改善了关键步行参数,如步行速度和步伐长度.
科学领域:
- 神经康复疗法 神经康复疗法
- 儿科物理治疗 儿科物理治疗
- 唐氏综合征研究 唐氏综合征研究
背景情况:
- 沃伊塔疗法 (VT) 是一种神经康复技术,专注于姿势功能.
- 现有研究表明,静脉可以改善步态,但它对唐氏综合征 (DS) 患者的直接影响还未得到充分研究.
研究的目的:
- 评估单个Vojta疗法会话对唐氏综合征患者的步行参数的直接影响.
- 提供关于VT在改善DS人群的步态效果的初步数据.
主要方法:
- 一项非随机试点研究,涉及16名唐氏综合征患者 (平均年龄为17.88岁).
- 参与者接受了一次由合格的物理治疗师管理的Vojta疗法.
- 在VT干预之前和之后,使用Vicon运动捕捉系统测量了时空步行参数.
主要成果:
- 在静脉训练课后的步行速度,节奏,步长,步长和双重支时间 (P <0.05) 中观察到显著的改善.
- 正确的步骤时间也显示了显著的改善.
结论:
- 一次Vojta疗法会话可能会为唐氏综合征患者的步态带来即时的好处.
- 建议进行进一步的大规模研究,以调查综合性VT计划的长期影响.
相关概念视频
Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
Parkinson's Disease: Overview
452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452

